Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBB0979
- Development stage
- Phase 2
- Lead developer
- SUNHO BioPharmaceutical
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
IBB0979 is a potential first-in-class immunocytokine designed for the treatment of locally advanced or metastatic solid tumors. It is composed of an antibody moiety targeting B7-H3 (CD276), which is overexpressed in a wide range of cancers, fused to interleukin-10 (IL-10). The drug acts as both a B7-H3 agonist and an IL-10 agonist, aiming to deliver IL-10 specifically to tumor sites and activate immune cells such as CD8+ T cells and potentially NK cells within the tumor microenvironment. Developed by SunHo BioPharmaceutical, IBB0979 has received IND approval from both the FDA and NMPA and is currently being evaluated in Phase 1/2 clinical trials for advanced solid tumors[1][3][5]. Its administration routes include intravenous and subcutaneous injection.
- Other names
- B7H3-IL10 immunocytokineB-7H3-IL10 immunocytokineB 7H3-IL10 immunocytokine
02
Targets
IL10RA (Interleukin-10 Receptor)B7-H3
Beyond the preview
Go deeper on IBB0979.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBB0979.